These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32569222)

  • 1. Comparison of HAS-BLED with other risk models for predicting the bleeding risk in anticoagulated patients with atrial fibrillation: A PRISMA-compliant article.
    Zeng J; Yu P; Cui W; Wang X; Ma J; Zeng C
    Medicine (Baltimore); 2020 Jun; 99(25):e20782. PubMed ID: 32569222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores.
    Proietti M; Senoo K; Lane DA; Lip GY
    Sci Rep; 2016 Apr; 6():24376. PubMed ID: 27067661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin.
    Senoo K; Proietti M; Lane DA; Lip GY
    Am J Med; 2016 Jun; 129(6):600-7. PubMed ID: 26482233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis.
    Caldeira D; Costa J; Fernandes RM; Pinto FJ; Ferreira JJ
    J Interv Card Electrophysiol; 2014 Sep; 40(3):277-84. PubMed ID: 25012972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    Am J Med; 2018 May; 131(5):574.e13-574.e27. PubMed ID: 29274754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive abilities of the HAS-BLED and ORBIT bleeding risk scores in non-warfarin anticoagulated atrial fibrillation patients: An ancillary analysis from the AMADEUS trial.
    Senoo K; Lip GY
    Int J Cardiol; 2016 Oct; 221():379-82. PubMed ID: 27409565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Accuracy of the HAS-BLED Bleeding Score in VKA- or DOAC-Treated Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Gao X; Cai X; Yang Y; Zhou Y; Zhu W
    Front Cardiovasc Med; 2021; 8():757087. PubMed ID: 34881309
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparing Bleeding Risk Assessment Focused on Modifiable Risk Factors Only Versus Validated Bleeding Risk Scores in Atrial Fibrillation.
    Guo Y; Zhu H; Chen Y; Lip GYH
    Am J Med; 2018 Feb; 131(2):185-192. PubMed ID: 28943382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS-BLED and GARFIELD-AF Bleeding Scores.
    Proietti M; Rivera-Caravaca JM; Esteve-Pastor MA; Romiti GF; Marin F; Lip GYH
    J Am Heart Assoc; 2018 Sep; 7(18):e009766. PubMed ID: 30371183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative validation of HAS-BLED, GARFIELD-AF and ORBIT bleeding risk scores in Asian people with atrial fibrillation treated with oral anticoagulant: A report from the COOL-AF registry.
    Chichareon P; Winijkul A; Lip GYH; Krittayaphong R
    Br J Clin Pharmacol; 2023 Aug; 89(8):2472-2482. PubMed ID: 36942465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of HAS-BLED and other bleeding risk assessment tools in predicting major bleeding events in atrial fibrillation: A network meta-analysis.
    Chang G; Xie Q; Ma L; Hu K; Zhang Z; Mu G; Cui Y
    J Thromb Haemost; 2020 Apr; 18(4):791-801. PubMed ID: 31782613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
    O'Brien EC; Simon DN; Thomas LE; Hylek EM; Gersh BJ; Ansell JE; Kowey PR; Mahaffey KW; Chang P; Fonarow GC; Pencina MJ; Piccini JP; Peterson ED
    Eur Heart J; 2015 Dec; 36(46):3258-64. PubMed ID: 26424865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study.
    Apostolakis S; Lane DA; Guo Y; Buller H; Lip GY
    J Am Coll Cardiol; 2012 Aug; 60(9):861-7. PubMed ID: 22858389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy.
    Roldán V; Marín F; Fernández H; Manzano-Fernandez S; Gallego P; Valdés M; Vicente V; Lip GYH
    Chest; 2013 Jan; 143(1):179-184. PubMed ID: 22722228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
    Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HAS-BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis.
    Zhu W; He W; Guo L; Wang X; Hong K
    Clin Cardiol; 2015 Sep; 38(9):555-61. PubMed ID: 26418409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive ability of HAS-BLED, HEMORR2HAGES, and ATRIA bleeding risk scores in patients with atrial fibrillation. A French nationwide cross-sectional study.
    Fauchier L; Chaize G; Gaudin AF; Vainchtock A; Rushton-Smith SK; Cotté FE
    Int J Cardiol; 2016 Aug; 217():85-91. PubMed ID: 27179213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of HAS-BLED and ORBIT bleeding risk scores in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: a report from the ESC-EHRA EORP-AF General Long-Term Registry.
    Proietti M; Romiti GF; Vitolo M; Potpara TS; Boriani G; Lip GYH
    Eur Heart J Qual Care Clin Outcomes; 2022 Oct; 8(7):778-786. PubMed ID: 34555148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the CHA
    Yao X; Gersh BJ; Sangaralingham LR; Kent DM; Shah ND; Abraham NS; Noseworthy PA
    Am J Cardiol; 2017 Nov; 120(9):1549-1556. PubMed ID: 28844514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial.
    Proietti M; Hijazi Z; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Lane DA; Oldgren J; Roldan V; Yusuf S; Wallentin L;
    J Intern Med; 2018 Mar; 283(3):282-292. PubMed ID: 29044861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.